NEO

Company Overview — What Does NEOGENOMICS INC Do?

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida. NEOGENOMICS INC (NEO) is classified as a small-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO Christopher M. Smith and employs approximately 2,100 people, headquartered in FORT MYERS, Florida. With a market capitalization of $1.0B, NEO is one of the notable companies in the Industrials sector.

NEOGENOMICS INC (NEO) Stock Rating — Reduce (April 2026)

As of April 2026, NEOGENOMICS INC receives a Reduce rating with a composite score of 35.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NEO ranks #3,653 out of 4,446 stocks in our coverage universe. Within the Industrials sector, NEOGENOMICS INC ranks #628 of 752 stocks, placing it in the lower half of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NEO Stock Price and 52-Week Range

NEOGENOMICS INC (NEO) currently trades at $7.84. The stock lost $0.10 (1.3%) in the most recent trading session. The 52-week high for NEO is $13.74, which means the stock is currently trading -42.9% from its annual peak. The 52-week low is $4.72, putting the stock 66.1% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.

Is NEO Overvalued or Undervalued? — Valuation Analysis

NEOGENOMICS INC (NEO) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.25x, versus the sector average of 2.23x. The price-to-sales ratio is 1.49x, compared to 0.50x for the average Industrials stock.

At current multiples, NEOGENOMICS INC trades at a premium to most Industrials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NEOGENOMICS INC Profitability — ROE, Margins, and Quality Score

NEOGENOMICS INC (NEO) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -13.9%, compared to the Industrials sector average of 8.9%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.5% versus the sector average of 3.3%.

On a margin basis, NEOGENOMICS INC reports gross margins of 43.4%, compared to 35.8% for the sector. The operating margin is -17.5% (sector: 6.2%). Net profit margin stands at -16.3%, versus 3.9% for the average Industrials stock. Revenue growth is running at 14.2% on a trailing basis, compared to 6.4% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NEO Debt, Balance Sheet, and Financial Health

NEOGENOMICS INC has a debt-to-equity ratio of 41.0%, compared to the Industrials sector average of 70.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.26x, indicating strong short-term liquidity. Total debt on the balance sheet is $342M. Cash and equivalents stand at $164M.

NEO has a beta of 1.08, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NEOGENOMICS INC is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

NEOGENOMICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, NEOGENOMICS INC reported revenue of $705M. Net income for the quarter was $-116M. Gross margin was 43.4%. Operating income came in at $-124M.

In FY 2025, NEOGENOMICS INC reported revenue of $727M. Net income for the quarter was $-108M. Gross margin was 43.2%. Revenue grew 10.1% year-over-year compared to FY 2024. Operating income came in at $-116M.

In Q3 2025, NEOGENOMICS INC reported revenue of $188M. Net income for the quarter was $-27M. Gross margin was 42.8%. Revenue grew 11.9% year-over-year compared to Q3 2024. Operating income came in at $-27M.

In Q2 2025, NEOGENOMICS INC reported revenue of $181M. Net income for the quarter was $-45M. Gross margin was 42.6%. Revenue grew 10.2% year-over-year compared to Q2 2024. Operating income came in at $-48M.

Over the past 8 quarters, NEOGENOMICS INC has demonstrated a growth trajectory, with revenue expanding from $165M to $705M. Investors analyzing NEO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NEO Dividend Yield and Income Analysis

NEOGENOMICS INC (NEO) does not currently pay a dividend. This is common among smaller companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.

NEO Momentum and Technical Analysis Profile

NEOGENOMICS INC (NEO) has a momentum factor score of 33/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

NEO vs Competitors — Industrials Sector Ranking and Peer Comparison

Within the Industrials sector, NEOGENOMICS INC (NEO) ranks #628 out of 752 stocks based on the Blank Capital composite score. This places NEO in the lower half of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.

Comparing NEO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NEO vs S&P 500 (SPY) comparison to assess how NEOGENOMICS INC stacks up against the broader market across all factor dimensions.

NEO Next Earnings Date

No upcoming earnings date has been announced for NEOGENOMICS INC (NEO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NEO? — Investment Thesis Summary

The quantitative profile for NEOGENOMICS INC suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Momentum is weak at 33/100, a headwind for near-term performance. High volatility (stability score 38/100) increases portfolio risk.

In summary, NEOGENOMICS INC (NEO) earns a Reduce rating with a composite score of 35.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NEO stock.

Related Resources for NEO Investors

Explore more research and tools: NEO vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NEO head-to-head with peers: NEO vs SOBO, NEO vs TEN, NEO vs GLDD.